CMPS - Earnings call transcript Q4 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to COMPASS Pathways Limited Fourth Quarter 2024 Investor Call. [Operator Instructions] I will now hand today's call over to Steve Schultz, Senior Vice President of Investor Relations. Please go ahead, sir.

Stephen Schultz

Welcome, all of you, and thank you for joining us today for our fourth quarter 2024 results conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways.

Kabir Chief Chief have Financial by Teri Officer; prepared joined our Loxam, Officer, I'm Nath, Executive our and remarks. Today, who will

Lori Officer; Dr. our will our be addition, Guy the our Officer, Medical In Q&A. for Goodwin, Chief Patient Chief Dr. and Officer; Commercial available Steve Levin, Chief Englebert,

a Relations days. and recorded the conclusion after being is available will call shortly available will be XX on the website call period the The and Compass be for Pathways of Investor of

Before me will the making Litigation meaning let XXXX we today, forward-looking call Private of the the during begin, as that everyone remind amended. within the Securities be team Act of Reform statements

on and a factors, risks report including Risk You in Compass made risks, by and annual our implied expressed Actual SEC. forward-looking other under or statements. results result recent uncertainties Securities any subsequent and from should U.S. filings reliance events Exchange statements most forward-looking of XX-K those not by place the various heading uncertainties with as described these could the with in undue and Commission those or differ Form Factors on the filed materially

statements, statements relied if of We today as views our should not even our any obligation views change. and disclaim specifically estimates assumptions revise be forward-looking only forward-looking any or these upon Additionally, any our represent representing date. or as of as subsequent update to

Kabir call Nath. to the hand over now I'll

Kabir Nath

Thank thank you, for Steve. day, Good everyone, and us. you joining

to of received financing success. from and for IIa beyond January years the readouts an our last COMP Compass program positions also us couple development exciting month. who open-label a in we for us Phase thanking the This to multiple begin program but our by investors the importantly, financing me with data last XXX us not positions will encouraging upcoming progress our be This May. participated TRD, allows PTSD existing new that study and in only Let results complete well

line As so the year. call, third primary in of in from on within top endpoint XX% We've quarter from we're results end this we recruitment, the quarter the which trial over of await trial will we complete. recruited to X-week patients earnings of of second XXX once the guided sight the the enrollment we announce eagerly the is

intervals. and with the in these As clear when quarter, should associated we'll available between validation a the efficacy investors We line treatment disclosing The for a difference with strong confidence the arms, effect provide become be of believe that endpoint. X treatment the understanding together a our reminder, results provide in COMPXXX IIb TRD. X-week for for data effect, if the the top the measures Phase potential primary key positive, MADRS and p-value results second

that standpoint, basis. a assessment safety is reviews trial the independent regular blinded from weeks, a the unblinded a through high-level which data From on continuing XX safety given we'll provide DSMB

to XXX III trial, well over second high throughput sites the will sites upon enrollment going For XXX completing trial, the XXX. and Phase enrollment is in XXX which the convert is

excited for of half of momentum the in gaining the we're out So second results we're read to XXXX. and XXX XX-week

internally discussion various clinical COMPXXX program. our plans the the able resume refining as a of we're is both working address recent in We're given to the and clinical potential the with questions scope through of earlier, mentioned of financing under we're well As process as to now development and advisers. PTSD, external which the for designs, for late-stage

possible. PTSD those We on progress. as quickly Our primary our updating as as who to suffer to to goals forward plans and get success to are look of you they probability maximize from the COMPXXX

psychiatry with important networks select commercial care Finally, our insights the the settings. including into collaborations interventional strategic are care providing organizations, on front, health various delivery

strategy SPRAVATO within is to Insights, these using launch post-launch scaling. inform models. identify Many are organizations COMPXXX their and which operating of opportunities our particularly now, scale for helpful which to delivering we're as we

our is to III the will based will -- full Phase differentiated meaningful COMPXXX us acting treatment a believe clarity on we on our date, give profile clinically have data While with we data rapid that durability.

the to now call me over the Let hand for Teri financial update.

Teri Loxam

the operations Kabir. the provided year that we I'll through Cash the in $XXX.X million now results. million, step used year $XXX to for Thank $XXX last full of within financial year guidance was full million. you, range

compared of $XXX.X share during the For in million million was same with loss year the $X.XX net loss $X.XX net or period share XXXX, XXXX. or $XXX.X ended per a XX, December per

in noncash under XXXX. $XX.X million million in facility the These of XXXX loan $XX.X million in G&A at the Debt Hercules XXXX were prior include compared $XX.X fourth $XX.X year. R&D XXXX million was $XX.X $XXX expenses share-based compensation with million the in million quarter. the of with and million the were prior in year. in end $XX.X expenses results compared

million. At December XX, of cash and XXXX, we had equivalents cash $XXX.X

fund January proceeds million, completed with together the which half readout As the approximately to of which resulted is a data second $XXX end million of the XXXX. provides of this we which planned our of year, operations the year, study, the at from us cash at our XX-week $XXX through Kabir we COMPXXX in in had of financing, mentioned, expected in that runway least net

we be the expect to financial full in of of used to year cash guidance, $XXX operations XXXX net million. the for range million $XXX within XXXX Regarding

back Thank over Kabir. you, and turn I'll now call the to

Kabir Nath

Teri. you, Thank

pivotal ahead program. our exciting an from years multiple with have III Phase couple readouts data We of

end completed top endpoint once quarter. data X-week that we of next the to then have trial. of line XX-week primary the and data report XXX XXX, A towards all participants For expect the Part

the we disclose in of to half For expect that XX-week the trial, XXXX. XXX results second

in options limited see to In potentially continuing paradigm-changing we treatment launch need commercial the treatment prepare current opportunities for parallel, higher we're the PTSD. this and of significant given and TRD

Goodwin, of Levin Guy Steve Dr. beginning Q&A. mentioned Lori call, Thank As Dr. and also Engelbert the you. will available for be at the

for back Q&A. I And the turn to now will the operator call

Operator

line first is of question the EviCore with ISI. from Your Clark-Gartner Instructions] [Operator Gavin

Gavin Clark-Gartner

So the in Do a initial bar believe X-week think should line. XXX points. you a Phase I for delta that the the bit reasonable top IIb X above be was MADRS

Kabir Nath

Gavin, And just hear check, it's to Kabir. you can us clearly.

Gavin Clark-Gartner

Yes.

Kabir Nath

Thank Yes. Great. you.

for benchmark X-week I we So the IIb used Phase that have consistently as we've how plan think, Phase and studies. IIb from said we as for the powering the III Phase the data the

number we said planning have So the yes, Phase But in reasonable. that guide reminder of terms what Again, significantly is I the used think III. that size. clinically you a is a lower in effect is meaningful that

Gavin Clark-Gartner

to that And the Okay. the will committee you maybe your development. for Great. anything PTSD inform learn upcoming just advisory there's on side, frame could if you're looking meeting, just

Kabir Nath

upcoming meeting, AdCom the yes. So mean, you BREC

Gavin Clark-Gartner

Yes, correct.

Kabir Nath

we'll something Well, spread that's that of with interested result thought lives, population of different complexity be the PTSD in the some and develop. of of that the who a -- lives of the of how also in certain PTSD trauma amount kinds basically view the requires they patient patients because of early

scores, how regulatory clinically trials. endpoint of things. the the that's be actual in the is in So both new the Obviously, research CAPS-X, in for relatively interested of will one a view issue which still they indeed use we in and key the I difference think and

for response think I interpret and terms us of about that in informative think will they remission, we in in changes how us be our So will that studies. guide how

guidance deal fact I us of beyond doesn't It the placebo our a response be great offer don't here think will given arm that, placebo might what as like. really that the placebo. look daily to

course, we'll, tuning but limitations, So there in. we'll are of be

Operator

question Paul next Mattis the is Your Staples. line from of with

Unknown Analyst

bit going disclosed in potential the the I to is safety the well upcoming on you can readout? know high-level just ideation. talked about actually This what's about top Julian line SMB be and commentary as at from for guess, as COMPXXX I a talk some you Paul. little for

So commentary helpful. on be would just any that

And also, enrolling? are -- are color enrollment track? any you And on then just studies these on still

Kabir Nath

Happy both of to No, take thanks. those.

that with arms, confidence said is X-week an terms will effect P disclosing, going size, the and of in the the the MADRS it be suicidal it in we've data, ideation. to we between on the DSMB, So will as anything specifically a from whether from a as they with of to efficacy the From size what consistently associated value statement difference. difference including see you've perspective, be imbalance be developments terms said, as safety perspective, clinically in effect concerning

in And now and fact, on for in basis. amendment. just preceded the call, trial. terms for over month, us just XXX, on said I unblinded that are change, recruited recruitment, a have safety seeing is recently, without reminder, the to we as without Most this direct a And of XX% data DSMB regular

XXX is that the So much within at to we're sight end well. of very recruit continuing

now XXX over One that's process of exquisite start said, into XXX, as the again, detail. is, roll we've factors high-performing we planning will can and with there a sites that

we so of to continue XXX XX-week second now be on for half data XXXX. track the for in And

Operator

next question. line, is Duncan go line open. Mr. There's line Cantor. from your comes Your we'll no question next the of Charles, the from with Charles Duncan's response to

Your Baral next Ritu question is from of with TD Cowen. the line

Ritu Baral

MADRS with the analysis? sort get and play as that to far play? to in getting regulators how means? Will will relative -- be . and else do will relation you what Kabir, well? additional line the importance still And remissions scales as line any top think and responses top as How we we will of will both get we secondary clinicians

Kabir Nath

Thanks, Ritu.

going X-week anything be going getting on or the to not the actually effect any with difference data, size remission we be to MADRS to secondaries. data. It is with going not X-week the be getting literally We're no, just be response So to else. clear, are

Ritu Baral

disposition percentage Got out? and then or how -- expectations. about on that the finally not Can tolerability comes demographic and at you has the may background final up has patient XX% impact you enrolled, data SSRIs your talk it. what to are shaped efficacy how that as come And in and may

Kabir Nath

Thanks.

not numbers seeing aren't I similar broken in in the go. from what it of respects, we're saw on that again, drugs in My other number can't actually statistic We patients that a the goes. down just is we we of just seeing detail precise II. That's at for example, the of give We're of exposures. But of that we -- been to the the you washout as comorbidities, that as Phase at our impression the kind in details looking -- we part as not protocol. aren't numbers looking use go

Ritu Baral

line, And it. top with the to be. you will study powering Got of the release what designed was

Kabir Nath

to I interested, that if we Yes. the be data. we'd once guess share happy you're have

Operator

Your line Duncan question the Cantor. Charles of is next with from

Charles Duncan

if wondering the Congrats line regard suicidal recent with could and me. ideation. a question hear can of meeting, previous on of a I on you guess Wanted added you I'm the would color to up what I appreciate -- terms follow anticipate you color. Hopefully, top to for provide bit little DSMB in

a past. out that in I happens would We've population, talked provide have about patient this patient population. this but more information the little on it expected what in you know of

Guy Goodwin

And collect we the ideation. contextualized. the it whole be events using have we'll Charles, able rating we're a suicidal to that expect Guy population, the due serious suicidality Columbia as In see here. mean saw extent we you the scale. be know, to for course, do basis I to to Obviously, systematic we collecting that scale. using adverse which on summarize

is And our it's because can't that DSMB from is do to own that what unblinded. do We perspective. able the

reason of decide judgment danger. trial to that in So on is there we clear think to a that happening no the signal what rely represents clinical is their

rely they So what trust that look judgment clinical feed and back the all on at have we essentially, to we information, to us. to their of

Teri Loxam

might patient But we you reason worth of And because the probably Guy, ideation adding. see it's is the suicidal population.

So that, not want our to and of may on expand necessarily part it's you drop.

Guy Goodwin

read, mean was the carries that to suicide. of it but taking I of with I needs that suicidality No. be carries has depression sort and attempted suicidality risk inherently restated as with that Yes. completed perhaps or

is risk particular, individuals large no we patients in is risk. that to but that for treatment-resistant that, who trying the number any of with that is So risk. depression, the there enrolls study Obviously, minimal ensure running study, the enter condition the carries doubt are that a

Charles Duncan

review, DSMB are that Yes, would looking that and if to have if were events at I there sense. know get tracking But been correct? you that there the makes that. with regard any and they

Guy Goodwin

concerned about if that they occurred were about. We would have Yes. full they the that know and have events information

Operator

the from is Timashev, RBC. question Leonid . next Your line of

Leonid Timashev

I receiving I little guess the receiving I And real-world about response maybe again. how I their just it rather are SSRI if start mean, the medication like FDA something aspect the to durability us side, first dose? chooses a is then the measuring thinking their COMPXXX different still COMPXXX? how their want dose durability practical after that get medication starts does part is guess, the And you after bit win about future Can to talk other or on of an to guys remind how than the if a patients start you're and more all, patient in maybe back retain coming of that? someone another think dose? to you second

Guy Goodwin

I early followed the response in over we cases as that guess weeks, that II response way up maintained Phase many as MADRS know, many patients. see see in weeks, that we was that, is very that the Okay. we study we obvious XX change from we which in a to baseline the X know you that and see durability a in of

that There the time ways you've implied That be treatment durability and capturing new will we study of X the will new we that to And in be soon capturing of a the II, and to affect in sense, is of that. our our publicly a treatment intervention which treatment. course, look and time that conduct be for available another is in study. Phase we doesn't publication. in one indeed, data the it But an at can the new will captured also

not remain with protocol something comment FDA's what can within have The attitude that to our on. I and is patients XX-week the up followed us obviously

to to to data a maintenance speak I that reach perspective I the a can wouldn't But they'll patients good We actually if symptomatic response antidepressants. be judgment. and want clinical will surprised go think a them, I deliver make from on to may

a I of very unsurprising one therefore, may well And is think that be which be in would be if ways durability that, very team. that it that the happened. can

Operator

response next to of from Brisebois Francois Wainwright. question. from is We'll with question Trucchio line no Your line. the with go Oppenheimer. next H.C. François Patrick There is the

Patrick Trucchio

just we A MADRS guess relation would couple of And contextualize at other comp a questions X TRD me. be I clinically from be in treatments? improvement how on X meaningful would psilocybin in prior the the to what the and total should weeks? follow-up first score considered trials at the readout results

from perspective, psychological saw And of sort support could the And support provide some secondly, model in just on of perspective. I what how if from then commercialization wondering implementation? should we also in details experience? with scale-up and how terms was And you terms just model. this of the a think the is but psychological regulatory different we about the a

Kabir Nath

Thanks, Patrick.

on of active to Guy. clear just in see difference reminder, couple arms, that, MADRS the just there, hand the to that. going to a going We're I'll the a the So on be before and between But arm. you're not to effect difference see just questions

and talk support . initially side a and from So that on to to But to Guy on again, about the me just perspective. scaling on that Laurie to to then remind pass then that. comment let psychological

Guy Goodwin

Yes. more that. I add has won't to really I really much the be mean Kabir what difference on because said can't reporting we

you've change again. in Phase order II of immediate very the that As be of course, saw was points we seen we'd of on happy study, the our if MADRS. XX And the

that easy to is isolation I to potential I understand for what model, efficacy make psychotherapy. to effects important from understand any think think the is the from on support do what psychological is drug's to it FDA trying we're in the

and the gives It for they on them that gives it reason, experience. to the that we essentially afterwards. chance we supports about need so patients talk them support it for to the a for the them simplified so offer And day information it have

are to And ensure to about them We it's approach considerable to sitting trained that very do much what to them people to following practice protocol. is follow trained that our systematizing essentially have sessions protocol have clinical is and with the a really degree. trial a the follow monitoring And we what we patients the so unlike more a will do. we're do we all able of exactly that be

And that frankly, amount patients assumptions come about required has with who in certain of retraining, for more a psychotherapy.

to So of to want that's on the comment I'll pass the Lori, implications clinical... approach who trials. our to may

Lori Englebert

Yes.

drug of what launch in are right limited we licensed what that have support and requirements is up drug to time. think and to end model constrained the I will health as administration be and are will purpose Guy and sure therapists not that hopefully, provider to to we be very scale said administration. at to the the terms than as that as administration up SPERVATO we expect patients that through be well the of well, after care making only for don't drug prior And to REMS now, the a different at support

Unknown Executive

And psychiatric. saying in worth This is also It's just is X add. new medicine, in just protocol be a across common treatment not or thing to a new Steve that to trained Levin.

so we're budgets of that partners able our who a sites they're understand is allocate this one collaboration training. to of for they on to encompass being trained, right strategic being within is which areas how organization handful from now, but organizations And how hundreds also the the where trained learning focus of

this So moves terms it'll very into of care cynics. training in informed we as about be real real-world think how world

Operator

Your Brisebois next Frank with from question of Oppenheimer. is the line

FranÃ§ois Brisebois

me Can now? you hear guys .

Kabir Nath

Frank. can, Yes. We

FranÃ§ois Brisebois

Okay.

had IT issues. I've some Sorry,

comment Chief little -- I this what Steve And And was can was that? led of with making on this sorry well. wondering exactly to role if And just a Officer. a there, that if Patient more mentioned But you as implies? what just

Kabir Nath

and a that patient, the the question. Compass ahead that patients has trials providers' I'm we plant, to thinking a are I'm that. health really environment, in it's that placed our happy patients health whether incorporated to perspectives background, care very post-approval happy emphasis on -- the particularly the is such psychiatrist that but into as of asking about providers. where both care everything delivered actually both see an by think or patient ensuring by for design Thank you to licensed this answer to

this where what real-world really patient are needed and gets organization so the involved widely And there's rarified across perspective and that focused moves actually realistic that's that those outside to of of on broadly relatively clinical ensuring trials be voices is as I'm into may patients. the settings and a environment reflected

Unknown Executive

I I difficult patient it's a talk that of and self-evident we is be think, some a Frank, mean, experience. paradigm-changing silicon challenging supporting view what that we're the approach, of can I a through Yes. absolutely think changing and populations experience about the is And paradigm vulnerable point specifically from very a -- pretty it approach, patient

and So for who that better felt have within really was and Steve's having company, really experience somebody advocate and for of it. to Steve do to important than stand caliber we that the it

FranÃ§ois Brisebois

XX-week just comes you're when X Part data then XXX on us sharing of you out, week And XX And here guess what best XXX and remind terms week A just can for Great. the just in help just about should enrollment. Okay. timing us to data, timing. we of X how

Kabir Nath

continue we Frank. happy XXX. the So minimum to to XXX clearly completion have of invite gated is will I weeks at a be on mean you XX I'm of said Part A what to guess,

XXXX. have give weeks guidance we as enrollment now XX around to XXX, RF. for range clearer we a of lines, half second guidance the a in for XXX also fairly But position for time we specific the the wide are for and weeks XX obviously, more of get know, on you As given in

around we're guidance But not that. for now, timing specific giving

Operator

to go Kulkarni with question Morgan next next Sumant response. no the We'll There the Canaccord is Stanley. of question. go the Genuity. We'll line with to question. from is Purohit next Your Vikram

Sumant Kulkarni

actually X. I have

outweigh on So is scale. higher more and the to relevant that separation there might nonchronic in made would what an be than scenario. conventionally do earlier real that was some to considered bar the XXX question the hit Or comp . you world? clinically dosing But paradigm successful on point us to major relative think need

Kabir Nath

a hand mean in to reminder, precisely mean, approved I'll I So X this not Sumant, and MDD as this is but Guy, just I is... there's DRD. drugs

Guy Goodwin

Well, doesn't actually, the I honest we say should to the yardstick there the MDD. exist like else I think really that's anything on Is that? extended mean... in and anything exist answer, the

Unknown Executive

No.

So it's . a lower bar.

Kabir Nath

a lower bar MDD. Yes. If for anything, it versus TRD will be

Sumant Kulkarni

Understood.

to is XXX So the terms your CAM in II understanding require example? relatively the evolved our ahead get that be market data the seen far Phase how now compete the with ability of from to how to psychotic we've in that in given for that term your on is potential product some clinic, X-modMT, thinking compounds shorter with other -- times might able

Unknown Executive

This is one. I'll take that Steve.

amongst terms are viable of providers considerations, amongst decision-making them. I attractive economically think economics hopefully is for an whether health in considering from and them drives this proposition what the care key many

that the on And new procuring that so and the codes, day. it work did with for really which that, administration highlights Day we the X specific support are provided CPT category on

used a across approved, and hour-by-hour can be reminder, if on codes as those a an reported basis. they're of second elec treatments, range And

And will treatment, of reimbursed the of anticipate providers care the for we be providers length regardless for services the health provided. so that the

Teri Loxam

the these don't some will will now, need to TRD the quite be to indications approved think product our regardless you time, for psychedelic. of on of we also want LA TRD, Sumant, that about just some the I And be add right that mind, a maybe indication for.

Sumant Kulkarni

or some any enthusiasm support high regulatory for mean around process or might morale last there my at the at affected be into if changes . that the you terms medicines environment And and the say your of but seems here? either predictions interactions of potential in what you as the recent have would to that you have political in question, head how psychedelic current any personnel it. very FDA there might -- Got any, agency, tone with a levels

Kabir Nath

But don't very be question. tracking clear. things mean great yet we It straight answer know, Sumant. I obviously, you, is closely. a we And is are Thank to the

there at an instance, on. some worst, some combination overall think changes we And area these organizations are of for you on, in the this. our And think potentially, of neutral. about focused influence tailwinds and really perspective PTSD, of are the if positive that so is, I veterans haven't

that space that a can clearly be You in see tailwind. could

change So on. us terms FDA interaction, comment far, to in for no is of there

Operator

is Your Jason of the Maxim line from McCarthy with next question Group.

Michael Okunewitch

is the more I if Mike start This plans. Okunewitch your on line. to see could you a I bit off, guess talk little about just pipeline

you're in You a . PTSD. you Can while? talk been working did mention you're late-stage that some about a target study designing on? for of anorexia the indications has other know I a

Kabir Nath

Sure.

study, enrollment, So to that completed would on closed the anorexia we have XXXX we sometime data that. in and see expect

in a have now ahead, from IIs conducted full is on a right us given in interesting the that we've other focus steam number TRD indications. We have past and signals PTSD. of that development But our

Michael Okunewitch

in the right. like Do Travato, adoption see year. just we've just on than -- psychiatric seen then given All more this having TRD did And recent $X I if of for prepare that the in help inventional something could therapeutic you market wanted it could to COMPXXX. rise think billion another comment you

Unknown Executive

We absolutely do.

MDD of population. and that a patient done what in you seeing has what patients antidepressants, TRD job educating right with actually referred broadly a now, is the preparing is has TRD patient less the thinking X and if what failure And is we're are TRD million as patients addressable we on reminder, than probably and is. prior think X% about of about Spivato population, X as of Privado to J&J So about great HCPs around which really

the Surat bodes any for side only success So us additional to on market. well coming

Michael Okunewitch

progress. the on Congrats

Operator

is next with from the of line Stanley. Your Morgan question

Unknown Analyst

. hear Can me? you

Kabir Nath

Yes.

Unknown Analyst

for Vikram. This is Morgan on

imagine like you So of data to PTSD you're you what level disorder . prioritize you PTSD, what us of and needed? think looking follow-up could over different of walk bipolar for terms patients patients -- do on path then filing in studies, that is from PTSD. do number how X And the for in the other like through that you indications us One, exploring IIS?

Kabir Nath

Yes. Thanks, Morgan.

PTSD, So in nothing I be than I for mean, aware, approved think has as you'll years been XX more PTSD.

top focus was of intensity medical unmet terms seen and it perspective, us clear the scale to kind was therefore, list. our the that This Phase rose from absolutely of to the of problem, problem, the the of of commercial signal having area the both true in IIa. and an priority particularly in the So the need, around from that a a

the So on focus any of other PTSD ahead that's hence indication.

to a Now more to development Guy hand talk around I'll little the regulatory side.

Guy Goodwin

mean, out the the are in to trash we point. meeting of yet mean way a that. I I with way number carefully to Yes. on we the the FDA about to have process expect thinking in say we fixed obviously obviously we're that go. can't X that at of some PTSD. could And develop we've with scenarios a developed actually treatment I

population, the that's way for FDA's be obviously we'll insight the a take following little guidance brexpiprazole, observed. of some will in which from I AdCom the going us attitude place that the mean the into to from bit patient population give -- maybe is going -- have patient particular, of we're and also to the

the we're indications bipolar condition. co-medication and for other with mean you mentioned, little example, because I an a that yes, forward to looking exciting complexity more disorder, I simply this. the year of of So the difficult

PTSD, as administration. we so have that available Kabir this durability has massive There need. very data little has indicated, very, encouraging a after really very are this unmet and single

the place So first I that's to go. think clearly

We our that. have about no in minds doubt

Unknown Executive

has bit additional color. is long very X a well If PTSD right very now. out mind add There as Guy And million Yes, been a products I highly mentioned, time prevalent a population It FDA-approved very market. XX for little are about . mentioned, just only you as it's don't there. it's the in options. Morgan, happened patients limited of actually since Kabir And as innovation

Operator

of Your next Oppenheimer. from question line the is

FranÃ§ois Brisebois

here. X extra an Just

until recently, side, . DSMB Is On that how Or readout? had was. you comment no And assume it to what more? exactly this the that fair there said interaction can you XX% you just remind us are looks the X enrolled. DSMB made there be more seeing you at could of recent that

Kabir Nath

So the regular top as quarterly recent we in mean was it actually quarter. But the in of last in this the how as that's I line will hand so versus recent course when is quarterly. cadence kind of cadence have what guess, as happens is, February, month, next the I the in that we see to

Operator

At back further to closing remarks. no I this hand questions. call are will now there for the management time, over

Kabir Nath

Thanks very much.

everyone, today. and your for thanks, So time attention

the XXXX. exciting part of with towards start said, that we're we of about to we of And end the for line multiple in expect very Compass top couple excited quarter. at As years we're the data see latter particular, now a next XXX between and of the readouts

Thanks everyone. thanks, your So time. for

Operator

call. concludes joining. for you This today's Thank

You may now disconnect your lines.

COMPASS Pathways (CMPS) 27 Feb 252024 Q4 Earnings call transcript